A Case of Unresectable Combined Hepatocellular and Cholangiocarcinoma Treated with Atezolizumab Plus Bevacizumab

Naoto Saito,Takeshi Hatanaka,Sachi Nakano,Yoichi Hazama,Sachiko Yoshida,Yoko Hachisu,Yoshiki Tanaka,Teruo Yoshinaga,Kenji Kashiwabara,Kubo Norio,Yasuo Hosouchi,Hiroki Tojima,Satoru Kakizaki,Toshio Uraoka

Clinical case reports（2022）

引用 2|浏览0

暂无评分

摘要

An 81-year-old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangio-carcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5-month progression-free survival. Atez/Bev might exhibit efficacy for CHC patients.

查看译文

关键词

anti-programmed death ligand-1,hepatic resection,immune checkpoint inhibitor,liver cancer,vascular endothelial growth factor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要